Argenx announces positive CHMP Opinion for Vyvgart (efgartigimod alfa) subcutaneous injection for chronic inflammatory demyelinating polyneuropathy
Argenx SE announced the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended European Commission (EC) approval of Vyvgart 1000mg (efgartigimod alfa) for subcutaneous… read more.
